.beta.-Lactam antibiotics
AssigneeBeecham Group Limited
InventorMichael J. Driver
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof have antibacterial activity: ##STR1## wherein R is hydrogen, C.sub.1-6 alkylcarbonyl or C.sub.1-6 alkyl; R.sup.1 is hydrogen or hydrocarbon; R.sup.2 is hydrogen, or optionally substituted hydrocarbon or optionally substituted heterocyclyl or CXR.sup.d, where X is O or S and R.sup.d is hydrogen or optionally substituted hydrocarbon or optionally substituted heterocyclyl; or R.sup.1 and R.sup.2 together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl group. A process for the preparation of such compounds and compositions comprising them, are also described.
Claims30
A compound of the formula (I):
- ##STR12## or a pharmaceutically acceptable salt or in-vivo hydrolyzable ester thereof wherein R is hydrogen, alkylcarbonyl of 1 to 6 carbon atoms in the alkyl moiety or alkyl of 1 to 6 carbon atoms;
- R.sup.1 is hydrogen or a hydrocarbon;
- R.sup.2 is hydrogen, or an optionally substituted hydrocarbon or optionally substituted heterocyclyl or CXR.sup.d, wherein X is 0 or S and R.sup.d is hydrogen or an optionally substituted hydrocarbon or optionally substituted heterocyclyl;
- or R.sup.1 and R.sup.2 together with the nitrogen to which they are attached, for an optionally substituted heterocyclyl group.
6.beta.[D-2-(4-Ethyl-2,3-dio xopiperazine-1-carbonylamino)-2-(2,4-dihydroxyphenyl)]acetamidobisnorpenici llanic acid;
- 6,.beta.-[D,L-2(4-ethyl-2,3-dioxopiperazine-1-carbonylamino)-2-(3,4-dihdrox yphenyl)]acetamidobisnorpenicillanic acid;
- 6, .beta.[D,L-2[3-(3,4-diacetoxyphenylcarbonyl)-3-methyl -1-ureido]-2-(3,4-diacetoxyphenyl)]acetamidobisnorpenicillanic acid;
- 6, .beta.-[D,L-2(3-phenylcarbonyl-3-methyl-1-ureido)-2-(3,4-dihydroxyphenyl)] acetamidobisnorpenicillanic acid;
- 6, .beta.-[D-2[3-(4-chlorophenylcarbonyl)-3-methyl-1-ureido]-2-(3,4-dihydroxy phenyl)]acetamidobisnorpenicillanic acid or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
A pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises and antibacterially effective amount of a compound of the formula (I):
- ##STR14## or a pharmaceutically acceptable salt or in-vivo hydrolyzable ester thereof wherein R is hydrogen, alkylcarbonyl of 1 to 6 carbon atoms in the alkyl moiety or alkyl of 1 to 6 carbon atoms;
- R.sup.1 is hydrogen or a hydrocarbon;
- R.sup.2 is hydrogen, or an optionally substituted hydrocarbon or optionally substituted heterocyclyl or CXR.sup.d, wherein X is O or S and R.sup.d is hydrogen or an optionally substituted hydrocarbon or optionally substituted heterocyclyl;
- or R.sup.1 and R.sup.2 together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl group, in combination with a pharmaceutically acceptable carrier.
A method of treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof an antibacterially effective amount of a compound of the formula (I):
- ##STR16## or a pharmaceutically acceptable salt or in-vivo hydrolyzable ester thereof wherein R is hydrogen, alkylcarbonyl of 1 to 6 carbon atoms in the alkyl moiety or alkyl of 1 to 6 carbon atoms;
- R.sup.1 is hydrogen or a hydrocarbon;
- R.sup.2 is hydrogen, or an optionally substituted hydrocarbon or optionally substituted heterocyclyl or CXR.sup.d, wherein X is O or S and R.sup.d is hydrogen or an optionally substituted hydrocarbon or optionally substituted heterocyclyl;
- or R.sup.1 and R.sub.2 together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl group, in combination with a pharmaceutically acceptable carrier.
A pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises a .beta.-lactamase inhibitory amount of a .beta.-lactamase inhibitor and an antibacterially effective amount of a compound of the formula (I):
- ##STR18## or a pharmaceutically acceptable salt or pharamaceutically acceptable in-vivo hydrolyzable ester thereof wherein R is hydrogen, alkylcarbonyl of 1 to 6 carbon atoms in the alkyl moiety or alkyl of 1 to 6 carbon atoms;
- R.sup.1 is hydrogen or a hydrocarbon;
- R.sup.2 is hydrogen, or an optionally substituted hydrocarbon or optionally substituted heterocyclyl or CXR.sup.d, wherein X is O or S and R.sup.d is hydrogen or an optionally substituted hydrocarbon or optionally substituted heterocyclyl;
- or R.sup.1 and R.sup.2 together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl group, in combination with a pharmaceutically acceptable carrier.
A method of treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof a .beta.-lactamase inhibitory amount of a .beta.-lactamase inhibitor and an antibacterially effective amount of a compound of the formula (I):
- ##STR20## or a pharmaceutically acceptable salt or pharmaceutically acceptable in-vivo hydrolyzable ester thereof wherein R is hydrogen, alkylcarbonyl of 1 to 6 carbon atoms in the alkyl moiety or alkyl of 1 to 6 carbon atoms;
- R.sup.1 is hydrogen or a hydrocarbon;
- R.sup.2 is hydrogen, or an optionally substituted hydrocarbon or optionally substituted heterocyclyl or CXR.sup.d, wherein X is O or S and R.sup.d is hydrogen or an optionally substituted hydrocarbon or optionally substituted heterocyclyl;
- or R.sup.1 and R.sup.2 together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl group, in combination with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.